No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
HRTX Heron Therapeutics
- 3.470
- +0.030+0.87%
Close May 22 16:00 ET
- 3.560
- +0.090+2.59%
Pre 08:56 ET
522.77MMarket Cap-6309P/E (TTM)
3.525High3.370Low3.64MVolume3.440Open3.440Pre Close12.60MTurnover3.24%Turnover RatioLossP/E (Static)150.65MShares3.52552wk High-15.49P/B389.52MFloat Cap0.50052wk Low--Dividend TTM112.25MShs Float830.000Historical High--Div YieldTTM4.51%Amplitude0.500Historical Low3.465Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now?
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its First-Quarter Results
Heron Therapeutics, Inc. (NASDAQ:HRTX) just released its latest first-quarter results and things are looking bullish. Results overall were solid, with revenues arriving 5.1% better than analyst f
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
Express News | Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Comments
Heron Therapeutics' stock price surge may be positive, but the company's core business performance will decide the sustainability of this turnaround. Lack of profitability and minimal revenue growth could discourage potential investors.
Investors in Heron Therapeutics (NASDAQ:HRTX) From Five Years Ago Are Still Down 88%, Even After 21% Gain This Past Week 1
Heron Therapeutics' projected breakeven and profitability rely on optimistic growth estimates. The company's negative equity, possibly due to accounting methods, raises concerns.
📌Last week’s PDUFAs:
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
12
1
$Heron Therapeutics(HRTX.US$ anything gonna happen here today?
1
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg